Dakota Wealth Management Acquires Shares of 12,480 ResMed Inc. (NYSE:RMD)

Dakota Wealth Management acquired a new position in shares of ResMed Inc. (NYSE:RMDFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,480 shares of the medical equipment provider’s stock, valued at approximately $2,854,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. True Wealth Design LLC increased its position in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 110 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of ResMed during the third quarter worth approximately $34,000. Rosenberg Matthew Hamilton acquired a new position in shares of ResMed in the 4th quarter valued at $54,000. Capital Performance Advisors LLP purchased a new stake in ResMed in the 3rd quarter valued at $60,000. Finally, Quarry LP boosted its stake in ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 242 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Activity

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $248.74, for a total transaction of $497,480.00. Following the completion of the transaction, the director now owns 83,204 shares in the company, valued at approximately $20,696,162.96. The trade was a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the sale, the director now directly owns 6,723 shares in the company, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,099 shares of company stock worth $2,719,385. Company insiders own 0.71% of the company’s stock.

ResMed Price Performance

ResMed stock opened at $247.36 on Thursday. The company has a market cap of $36.31 billion, a P/E ratio of 32.76, a price-to-earnings-growth ratio of 1.79 and a beta of 0.70. ResMed Inc. has a one year low of $170.56 and a one year high of $260.49. The business has a fifty day moving average of $238.35 and a two-hundred day moving average of $233.80. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92.

ResMed (NYSE:RMDGet Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the firm earned $1.64 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. As a group, analysts predict that ResMed Inc. will post 9.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on RMD. Robert W. Baird lifted their price objective on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Stifel Nicolaus initiated coverage on ResMed in a research note on Friday, December 13th. They set a “hold” rating and a $250.00 price objective for the company. KeyCorp increased their price objective on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Bank of America boosted their target price on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. Finally, StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $233.09.

View Our Latest Research Report on ResMed

ResMed Profile

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

Further Reading

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMDFree Report).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.